340 related articles for article (PubMed ID: 26535512)
1. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
[TBL] [Abstract][Full Text] [Related]
2. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F; Fowler NH; Feugier P; Bouabdallah R; Tilly H; Palomba ML; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Daguindau N; Le Gouill S; Pica GM; Martin Garcia-Sancho A; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Zachée P; Sehn LH; Tobinai K; Cartron G; Liu D; Wang J; Xerri L; Salles GA;
N Engl J Med; 2018 Sep; 379(10):934-947. PubMed ID: 30184451
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Ruan J; Martin P; Christos P; Cerchietti L; Tam W; Shah B; Schuster SJ; Rodriguez A; Hyman D; Calvo-Vidal MN; Smith SM; Svoboda J; Furman RR; Coleman M; Leonard JP
Blood; 2018 Nov; 132(19):2016-2025. PubMed ID: 30181173
[TBL] [Abstract][Full Text] [Related]
4. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Ruan J; Martin P; Coleman M; Furman RR; Cheung K; Faye A; Elstrom R; Lachs M; Hajjar KA; Leonard JP
Cancer; 2010 Jun; 116(11):2655-64. PubMed ID: 20235190
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Martin P; Jung SH; Pitcher B; Bartlett NL; Blum KA; Shea T; Hsi ED; Ruan J; Smith SE; Leonard JP; Cheson BD
Ann Oncol; 2017 Nov; 28(11):2806-2812. PubMed ID: 28945884
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wen S; Wierda WG; O'Brien SM; Faderl S; Sargent R; Burger JA; Ferrajoli A
J Clin Oncol; 2013 Feb; 31(5):584-91. PubMed ID: 23270003
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Zinzani PL; Vose JM; Czuczman MS; Reeder CB; Haioun C; Polikoff J; Tilly H; Zhang L; Prandi K; Li J; Witzig TE
Ann Oncol; 2013 Nov; 24(11):2892-7. PubMed ID: 24030098
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Chang JE; Li H; Smith MR; Gascoyne RD; Paietta EM; Yang DT; Advani RH; Horning SJ; Kahl BS
Blood; 2014 Mar; 123(11):1665-73. PubMed ID: 24458437
[TBL] [Abstract][Full Text] [Related]
9. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
Griffiths R; Mikhael J; Gleeson M; Danese M; Dreyling M
Blood; 2011 Nov; 118(18):4808-16. PubMed ID: 21873544
[TBL] [Abstract][Full Text] [Related]
10. Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
Yamshon S; Chen GZ; Gribbin C; Christos P; Shah B; Schuster SJ; Smith SM; Svoboda J; Furman RR; Leonard JP; Martin P; Ruan J
Blood Adv; 2023 Nov; 7(21):6579-6588. PubMed ID: 37682791
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ; Feng L; Strati P; Lee HJ; Hagemeister FB; Westin JR; Samaniego F; Marques-Piubelli ML; Vega Vazquez F; Parra Cuentas ER; Solis-Soto LM; Ma W; Wang J; Claret L; Averill B; Ibanez K; Fayad LE; Flowers CR; Green MR; Davis RE; Neelapu SS; Fowler NH; Nastoupil LJ
Cancer; 2024 Mar; 130(6):876-885. PubMed ID: 37985359
[TBL] [Abstract][Full Text] [Related]
12. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Ujjani CS; Jung SH; Pitcher B; Martin P; Park SI; Blum KA; Smith SM; Czuczman M; Davids MS; Levine E; Lewis LD; Smith SE; Bartlett NL; Leonard JP; Cheson BD
Blood; 2016 Nov; 128(21):2510-2516. PubMed ID: 27697771
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy with
Jang YJ; Lim SM; Lee I; Byun BH; Lim I; Kim BI; Choi CW; Lee SS; Suh C; Yoon DH; Kim I; Nam SH; Lee MH; Won JH; Kong JH; Jeong SH; Oh SJ; Park KW; Han JJ; Song MK; Yang SH; Na II; Lee HR; Shin DY; Kang HJ
Asia Pac J Clin Oncol; 2023 Dec; 19(6):690-696. PubMed ID: 36915956
[TBL] [Abstract][Full Text] [Related]
15. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Rule S; Smith P; Johnson PW; Bolam S; Follows G; Gambell J; Hillmen P; Jack A; Johnson S; Kirkwood AA; Kruger A; Pocock C; Seymour JF; Toncheva M; Walewski J; Linch D
Haematologica; 2016 Feb; 101(2):235-40. PubMed ID: 26611473
[TBL] [Abstract][Full Text] [Related]
16. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Phillips TJ; Bond D; Takiar R; Kump K; Kandarpa M; Boonstra P; Mayer TL; Nachar V; Wilcox RA; Carty SA; Karimi YH; Nikolovska-Coleska Z; Kaminski MS; Herrera AF; Maddocks K; Popplewell L; Danilov AV
Blood Adv; 2023 Aug; 7(16):4518-4527. PubMed ID: 37013954
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A; Petrillo A; Della Pia A; Lee GG; Gill S; Varughese T; Zenreich J; Gutierrez M; Zhang J; Ahn J; Bharani V; Nejad AS; Pascual L; Feldman TA; Leslie LA; Goy AH
Leuk Lymphoma; 2023 Dec; 64(14):2225-2235. PubMed ID: 37740588
[TBL] [Abstract][Full Text] [Related]
18. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
Blood Adv; 2024 Jan; 8(2):407-415. PubMed ID: 38113470
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
[TBL] [Abstract][Full Text] [Related]
20. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Westin J; Davis RE; Feng L; Hagemeister F; Steiner R; Lee HJ; Fayad L; Nastoupil L; Ahmed S; Rodriguez A; Fanale M; Samaniego F; Iyer SP; Nair R; Oki Y; Fowler N; Wang M; Ma MCJ; Vega F; McDonnell T; Pinnix C; Griffith D; Lu Y; Tewari S; Sun R; Scott DW; Flowers CR; Neelapu S; Green MR
J Clin Oncol; 2023 Feb; 41(4):745-755. PubMed ID: 35952327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
